Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2001 | 1 |
2003 | 2 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and safety of recombinant human activated protein C for severe sepsis.
N Engl J Med. 2001 Mar 8;344(10):699-709. doi: 10.1056/NEJM200103083441001.
N Engl J Med. 2001.
PMID: 11236773
Free article.
Clinical Trial.
BACKGROUND: Drotrecogin alfa (activated), or recombinant human activated protein C, has antithrombotic, antiinflammatory, and profibrinolytic properties. ...
BACKGROUND: Drotrecogin alfa (activated), or recombinant human activated protein C, has antithrombotic, antiinflammatory, and …
Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G 3rd, Bernard GR; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group.
Vincent JL, et al.
Crit Care Med. 2003 Mar;31(3):834-40. doi: 10.1097/01.CCM.0000051515.56179.E1.
Crit Care Med. 2003.
PMID: 12626993
Clinical Trial.
INTERVENTIONS: A 96-hr infusion of drotrecogin alfa (activated) (human recombinant activated protein C) or placebo. MEASUREMENTS AND MAIN RESULTS: Sequential Organ Failure Assessment (SOFA) scores for cardiovascular, respiratory, renal, hematologic, and hepatic orga …
INTERVENTIONS: A 96-hr infusion of drotrecogin alfa (activated) (human recombinant activated protein C) or placebo. MEASUREMEN …
Item in Clipboard
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.
Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group.
Dhainaut JF, et al.
Intensive Care Med. 2003 Jun;29(6):894-903. doi: 10.1007/s00134-003-1731-1. Epub 2003 Apr 24.
Intensive Care Med. 2003.
PMID: 12712239
Clinical Trial.
Item in Clipboard
Cite
Cite